Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Go back to Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 3.12 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.12 | 52 Week High | $9.58 | |||
| Open | $3.12 | 52 Week Low | $2.34 | |||
| Day High | $3.12 | P/E | N/A | |||
| Day Low | $3.12 | EPS | $-0.34 | |||
| Volume | 8,734,059 | |||||
